News

Stanley Hsia, MD, Presents Phase 2 Trial Results for Mazdutide (GLP-1/Glucagon Dual Agonist)

At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss. Dr. Hsia: “All of these mazdutide treatment curves did not seem to plateau, suggesting that had we continued treatment beyond 48 weeks, greater degrees … Read more

Velocity Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer

Velocity Clinical Research, the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where he held senior leadership roles driving growth strategies and global business development. This appointment represents a pivotal … Read more

An Interview with Gerald Cephas, MD, on Advancing Psychiatric Research and Promoting Equity in Care

A research career wasn’t part of Gerald Cephas, MD’s original plan. He trained in general surgery, intending to specialize in pediatrics, but a health setback during residency changed his course. “Toward the end of residency, I got sick,” he explains. “So, long story short, research presented itself as a Plan B, and I’ve been on … Read more

Op-ed: How Data is Driving GenAI Solutions in Clinical Trials

By Tyler Beasley, Head of Business Intelligence at Velocity Clinical Research The future of successful clinical trials will be written in data. Generative AI (GenAI) is already transforming how Sponsors, CROs, and sites approach research, but the real impact will come when AI is deployed with scale and smart infrastructure. That’s where Velocity’s model gives … Read more

Winning Through Scale: How We’re Building Toward $500M Revenue

Investors care about many things, but when they say scale, they mean revenue. Two times, five times, ten times… whatever the directive, it’s centered on revenue growth. For leadership teams, the focus on revenue milestones is more nuanced. Each one matters to investors, yes. But each also marks a strategic shift. The decisions, disciplines, and … Read more

Potential Breakthrough to Preserve Lean Muscle Mass During GLP-1-Induced Weight Loss

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean … Read more

Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential … Read more

Velocity Appoints Dr. Sarah Smiley as Chief Physician Officer

Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more

Velocity Appoints Ines Abs as Country Head for Germany, Strengthening European Leadership Amid Market Consolidation

Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two decades of experience in clinical research operations, having held senior leadership … Read more